Q-omics provides the consensus-scored FER1L5 profile across patient tissues and cancer cell-line models. FER1L5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, FER1L5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FER1L5 RNA expression shows 17,050 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, THCA, and THYM as cancer lineages where FER1L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FER1L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FER1L5 survival associations across molecular data types. FER1L5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FER1L5 RNA expression–survival associations across cancer types. High FER1L5 expression shows unfavorable associations in ACC, LIHC and DLBC, but favorable associations in ESCA, LUAD and LAML. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for FER1L5 RNA expression.
This table summarizes FER1L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FER1L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FER1L5 shows lower tumor expression in THCA, KICH, KIRC and BRCA and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher FER1L5 RNA expression in normal versus tumor tissue (log2 FC = −0.279, t-test p < 0.001).
This table shows molecular features associated with FER1L5 in patient tissues and cancer cell lines. In patient samples, FER1L5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FER1L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
